Pharmac’s funding of Enhertu for Breast Cancer Patients w/ New Zealand Breast Cancer Foundation CEO, Ah-Leen Rayner

On Friday the 13th September, Pharmac opened consultation for funding of the medication, Enhertu, for HER2-positive metastatic breast cancer.

This comes following the $604 million funding boost allocated to Pharmac to fund and widen access to various medicines. 

Trials have shown that the drug can reduce risks of breast cancer patients death by 27%.

Producer Josef spoke to the Chief Executive of Breast Cancer New Zealand, Ah-Leen Rayner, about the drug's funding, and what more can be done for breast cancer patients.